3 powerhouse Houstonians named to the state's economic development board

Three's company

A oil and gas CEO, a serial entrepreneur, and a retail energy exec walk into the state capital. Getty Images

The Bayou City now wields some high-profile power in the state's economic development efforts.

The Texas Senate recently endorsed Gov. Greg Abbott's appointment of three business leaders with strong ties to Houston to the board of the Texas Economic Development Corp. — including the organization's new chair and vice chair.

Robert Allen, president and CEO of Texas' nonprofit economic development arm, says the Bayou City should feel well-represented on the board with former Houston Astros owner Drayton McLane as the new chair, Houston energy executive Vicki Hollub as the new vice chair, and Houston energy executive Scott Prochazka as a new member. That means Houston-connected business leaders hold three of the board's eight seats.

Allen calls McLane "the perfect Texas ambassador."

McLane, who lives in Temple, sold the Astros to Houston businessman Jim Crane in 2011 for $680 million. Forbes estimates McLane's net worth at $2.4 billion.

Today, McLane controls a Temple-based holding company with business interests such as food distribution, car dealerships and sports marketing. In 1991, he sold grocery distributor McLane Co. to Walmart, which later sold it to Warren Buffett's Berkshire Hathaway.

"I can think of no one better to lead our efforts to market the state of Texas as the best state for business than Drayton McLane. He has achieved tremendous success in several areas of business, all while calling Texas home," Allen tells InnovationMap.

McLane also chairs the board of Texas Central Partners, the Dallas company developing high-speed rail service between Houston and Dallas-Fort Worth. In addition, he serves on the boards of the George H.W. Bush Presidential Library Foundation, Baylor Scott & White Healthcare, and the Cooper Institute.

"I am privileged to be able to give service to our great state of Texas and honored by Gov. Abbott's appointment as chair of the Texas Economic Development Corporation," McLane says in a statement provided to InnovationMap.

"The goal of the corporation is to help market Texas as a place for businesses to grow and prosper," he adds. "Texas is a great state, and we have much to offer businesses in many sectors. I care deeply for Texas and improving the economy that will carry us into the future."

Hollub, president and CEO of Houston-based oil and gas company Occidental Petroleum, is the new vice chair of the Texas Economic Development Corp. She's spent 35 years at Occidental, which just hammered out a $57 billion deal to take over Anadarko Petroleum, an oil and gas company based in The Woodlands.

In addition to the board of the Texas Economic Development Corp., Hollub sits on the boards of Lockheed Martin and the American Petroleum Institute, and she is U.S. chair of the U.S.-Colombia Business Council.

"As the first female to head a major oil and gas company in the world, Vicki defines what it means to be a Texan — hardworking, determined, and incredibly smart," Allen says.

Prochazka, president and CEO of CenterPoint Energy, a Houston-based provider of electric and natural gas service, joins McLane and Hollub on the board of the Texas Economic Development Corp. Aside from his duties at CenterPoint, Prochazka is incoming chairman of the American Gas Association, chairman of Central Houston Inc., and a board member of the Greater Houston Partnership.

Given his roles with Central Houston Inc. and the Greater Houston Partnership, Prochazka knows Houston "intimately well," Allen says.

The Texas Economic Development Corp. is an independently funded and operated nonprofit that promotes economic development, business recruitment, and job creation in Texas. For instance, the nonprofit helped pave the way for a $15 billion liquefied natural gas (LNG) export facility in Corpus Christi that recently made its first cargo shipment. Houston-based Cheniere Energy owns the facility.

With Abbott's appointment of eight members, the makeup of the economic development organization's eight-member board is entirely new. The governor appointed them in April, but the state Senate had to give its final approval, which came earlier this month.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

UH med school gets $2M gift and more top Houston innovation news

Trending Topics

Editor's note: The top Houston innovation news of the month is full of fresh funding, with two Texas medical schools receiving major gifts — one of historic proportions. Below are the five most-read InnovationMap headlines from April 16-30, 2026.

UH med school granted $2M gift to offer student scholarships

A new scholarship endowment aims to support students in the University of Houston’s recently established medical school. The University of Houston’s Tilman J. Fertitta Family College of Medicine received a planned estate gift commitment estimated at $2.1 million to establish the Bob Diehl and Teresa Evans Diehl Scholarship Endowment. The scholarship will assist full-time medical students who demonstrate financial need and meet academic standards. Continue reading.

How Houston innovators played a role in the historic Artemis II splashdown

Research from Rice University played a critical role in the safe return of U.S. astronauts aboard NASA’s Artemis II mission this month. Rice mechanical engineer Tayfun E. Tezduyar and longtime collaborator Kenji Takizawa developed a key computational parachute fluid-structure interaction (FSI) analysis system that proved vital in NASA’s Orion capsule’s descent into the Pacific Ocean. The FSI system, originally developed in 2013 alongside NASA Johnson Space Center, was critical in Orion’s three-parachute design, which slowed the capsule as it returned to Earth, according to Rice. Continue reading.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March. Dr. Ryan S. Dhindsa hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation. Continue reading.

New UT Austin med center, anchored by MD Anderson, gets historic gift

A donation announced April 21 breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release. Continue reading.

Houston VC funding surged nearly 50% in Q1 2026, report says

Houston saw a jump in VC funding in Q1 2026, fueled by several major investments in clean energy startups. Image via Getty Images

First-quarter venture capital funding for Houston-area startups climbed nearly 50 percent compared to the same time last year, according to the PitchBook-NVCA Venture Monitor. In Q1 2026, Houston-area startups raised $532.3 million, a 49 percent jump from $320.2 million in Q1 2025, according to the PitchBook-NVCA Venture Monitor. However, the Q1 total fell 23 percent from the $671.05 million raised in Q4 2025. Continue reading.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

View All Listings